SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Pašlaik tiek pētīts 2. fāzes galvenajā izmēģinājumā, CART-ddBCMA ir Arcellx T-šūnu terapija, izmantojot uzņēmuma jauno sintētisko saistvielu D-domēnu. Kite un Arcellx kopīgi virzīs un komercializēs CART-ddBCMA aktīvu ASV, un Kite komercializēs produktu ārpus ASV.
CAR T-šūnu terapija ir viena no revolucionārajām metodēm noteiktu asins vēža veidu ārstēšanā. Pašlaik notiek vairāk nekā 750 klīniskie pētījumi in CAR T-Cell terapija Ķīnā tagadnē. Pacienti, kuri vēlas reģistrēties, var sazināties CancerFax pacientu palīdzības tālrunis vietnē WhatsApp +91 96 1588 1588 vai e-pastu uz info@cancerfax.com.
Par Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiplā mieloma (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk mielodisplastiskais sindroms, initiated in the fourth quarter of 2022.
Par Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Par Gilead Sciences
Gilead Sciences, Inc. ir biofarmācijas uzņēmums, kas vairāk nekā trīs gadu desmitus ir meklējis un guvis sasniegumus medicīnā ar mērķi radīt veselīgāku pasauli visiem cilvēkiem. Uzņēmums ir apņēmies attīstīt inovatīvus medikamentus, lai novērstu un ārstētu dzīvībai bīstamas slimības, tostarp HIV, vīrusu hepatītu un vēzi. Gilead darbojas vairāk nekā 35 valstīs visā pasaulē, un tās galvenā mītne atrodas Fostersitijā, Kalifornijā. Gilead Sciences iegādājās Kite 2017. gadā.
